Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.

Morgan SG, Thomson PA, Daw JR, Friesen MK.

Health Policy. 2013 Oct;112(3):248-54. doi: 10.1016/j.healthpol.2013.05.022. Epub 2013 Jun 25.

PMID:
23809914
[PubMed - indexed for MEDLINE]
Free Article
2.

Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.

Morgan SG, Thomson PA, Daw JR, Friesen MK.

BMC Health Serv Res. 2013 Jan 31;13:34. doi: 10.1186/1472-6963-13-34.

PMID:
23363626
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.

Morgan S, Daw J, Thomson P.

Health Aff (Millwood). 2013 Apr;32(4):771-7. doi: 10.1377/hlthaff.2012.1268.

PMID:
23569058
[PubMed - indexed for MEDLINE]
4.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
[PubMed - indexed for MEDLINE]
5.

Discounts and rebates granted to public payers for medicines in European countries.

Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A.

South Med Rev. 2012 Jul;5(1):38-46. Epub 2012 Jul 23.

PMID:
23093898
[PubMed]
Free PMC Article
6.

Drug pricing and value in oncology.

Danzon PM, Taylor E.

Oncologist. 2010;15 Suppl 1:24-31. doi: 10.1634/theoncologist.2010-S1-24.

PMID:
20237214
[PubMed - indexed for MEDLINE]
Free Article
7.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
[PubMed - indexed for MEDLINE]
8.

Differential pricing for pharmaceuticals: reconciling access, R&D and patents.

Danzon PM, Towse A.

Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. Review.

PMID:
14625999
[PubMed - indexed for MEDLINE]
9.

Pharmaceutical policies: effects of restrictions on reimbursement.

Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008654. doi: 10.1002/14651858.CD008654. Review.

PMID:
20687098
[PubMed - indexed for MEDLINE]
10.

Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.

Zhang S, Doucette WR, Urmie JM, Xie Y, Brooks JM.

Res Social Adm Pharm. 2010 Jun;6(2):121-9. doi: 10.1016/j.sapharm.2010.03.004. Epub 2010 May 7.

PMID:
20511111
[PubMed - indexed for MEDLINE]
11.

Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.

Kanavos P, Ferrario A, Vandoros S, Anderson GF.

Health Aff (Millwood). 2013 Apr;32(4):753-61. doi: 10.1377/hlthaff.2012.0920.

PMID:
23569056
[PubMed - indexed for MEDLINE]
12.

AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).

Academy of Managed Care Pharmacy.

J Manag Care Pharm. 2009 Aug;15(6 Suppl A):S3-57, quiz S58-61. Review.

PMID:
19678720
[PubMed - indexed for MEDLINE]
Free Article
13.

Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.

Vandergrift M, Kanavos P.

Health Policy. 1997 Sep;41(3):241-60.

PMID:
10170092
[PubMed - indexed for MEDLINE]
14.

The economics of parallel trade.

Danzon PM.

Pharmacoeconomics. 1998 Mar;13(3):293-304. Review.

PMID:
10178655
[PubMed - indexed for MEDLINE]
15.

Pricing and reimbursement of orphan drugs: the need for more transparency.

Simoens S.

Orphanet J Rare Dis. 2011 Jun 17;6:42. doi: 10.1186/1750-1172-6-42.

PMID:
21682893
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The impact of 1990 Medicaid drug rebates policy on access to prescriptions.

Okunade AA.

J Health Soc Policy. 2001;12(3):33-51.

PMID:
11146982
[PubMed - indexed for MEDLINE]
17.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005979. Review.

PMID:
16625648
[PubMed - indexed for MEDLINE]
18.

Drug policy: making effective drugs available without bankrupting the healthcare system.

Laupacis A, Anderson G, O'Brien B.

Healthc Pap. 2002;3(1):12-30. Review.

PMID:
12811107
[PubMed - indexed for MEDLINE]
19.

Drug reimbursement policies in Canada--need for improved access to critical therapies.

LeLorier J, Bell A, Bougher DJ, Cox JL, Turpie AG.

Ann Pharmacother. 2008 Jun;42(6):869-73. doi: 10.1345/aph.1K373. Epub 2008 May 13.

PMID:
18477735
[PubMed - indexed for MEDLINE]
20.

Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.

Stargardt T, Schreyögg J.

Appl Health Econ Health Policy. 2006;5(4):235-47.

PMID:
17249840
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk